Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance
Portfolio Pulse from
Merit Medical reported strong Q4 and FY 2024 results with significant revenue growth and improved operating margins. The company completed strategic acquisitions and received FDA approval for a new device. FY 2025 guidance indicates continued growth.
February 25, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merit Medical reported a 9.4% increase in Q4 revenue and a 7.9% increase for FY 2024. The company improved its non-GAAP operating margin and EPS, completed strategic acquisitions, and received FDA approval for a new device. FY 2025 guidance suggests continued growth.
Merit Medical's strong financial performance in Q4 and FY 2024, along with strategic acquisitions and FDA approval, are positive indicators for future growth. The FY 2025 guidance further supports a positive outlook, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100